Report an error   

Submitted: 22 November 2011 Modified: 04 March 2019
HERDIN Record #: PCHRD11221104112272

Post-marketing surveillance on the efficacy, safety and tolerability of Ziprasidone (Zeldox) in the treatment of schizophrenia and schizoaffective disorder.

Margaret B. Querijero,
Joan P. Manalo

OBJECTIVES: The primary objective of this trial was to evaluate the overall safety of oral ziprasidone among Filipinos diagnosed with acute exacerbation of schizophrenia and schizoaffective disorder based on the incidence of adverse events. Secondarily, the study was undertaken to evaluate the efficacy of oral ziprasidone based on the Clinical Global Impression (CGI)- Severity (S) and CGI-Improvement.

METHODS: Four thousand three hundred forty patients diagnosed with schizophrenia and schizoaffective disorders were to received Ziprasidone oral capsules. This was an open-label, multicenter study. The minimum expected duration of exposure to ziprasidone treatment for an individual subject was at least 2 weeks. Safety was based on the reported adverse event. Primary efficacy measures included the changes in CGI-S Score and weight and the CGI-I score at the end of treatment.

RESULTS: Among the 4,340 patients enrolled in the study, four thousand one hundred twenty seven (95%) patients completed the treatment, with 2% of the patients discontinue due to adverse events. 18% of the patients experienced adverse events which were mild to moderate in severity. Somnolence (3.2%) and dizziness (1.4%) were the most frequently reported adverse events.

CONCLUSIONS: Ziprasidone is a safe and effective treatment for Filipino patients diagnosed with acute exacerbation of schizoaffective disorder.

Publication Type
Publication Sub Type
Journal Article, Original
The Philippine Journal of Psychiatry
Publication Date
January-June 2005
LocationLocation CodeAvailable FormatAvailability
Philippine Council for Health Research and Development Library Box No.1 Fulltext Print Format (Request Document)
Philippine Psychiatric Association Fulltext pdf (Request Document)
1. Schultz, S , Andreasen , N . "Schizophrenia" Lancet 353, 1425-1430, 1999
2. Knapp, M . "Costs of schizophrenia" Br J Psychiatry 171, 509-18, 1997. Retrieved from:
3. American Psychiatric, . Practice Guidelines for the treatment of patients with schizophrenia 2001.
4. Perlas, AP , Lagrido-Ignacio, L , et al., . "The baseline regional survey of mental illness in the Philippines" , December 1994
5. American Psychiatric, . American Psychiatric Association Practice Guidelines for the treatment of patients with schizophrenia Washington, DC: American Psychiatric Press , 1997.
6. Kane , JM . "Treatment of schizophrenia " Lancet 34, 820-825, 1995
7. "Ziprasidone (Zeldox) Package insert" ,
8. Stimmel, GL , Gutierez, MA , Lee, V . "Ziprasidone:an typical antisychotic drug for the treatment of schizophrenia " Clin Ther 24, 1-37, 2002. Retrieved from:
9. Data on file. New York. 2004. Pfizer,

Copyright © One Window Project 2018. All rights reserved.